Scheduled versus Pro Re Nata Dosing in the VIEW Trials-Reference-Cited by-同舟云学术

Scheduled versus Pro Re Nata Dosing in the VIEW Trials

Published:2015-12 Issue:12 Volume:122 Page:2497-2503
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

Richard Gisbert,Monés Jordi,Wolf Sebastian,Korobelnik Jean François,Guymer Robyn,Goldstein Michaella,Norenberg Christiane,Sandbrink Rupert,Zeitz Oliver

Publisher

Elsevier BV

Subject

Ophthalmology

Reference10 articles.

1. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006

2. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial;Chakravarthy;Ophthalmology,2012

3. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration;Heier;Ophthalmology,2012

4. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Engl J Med,2006

5. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results;Martin;Ophthalmology,2012

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5;Eye;2024-05-06

2. Effect of Pro Re Nata Regimen with Anti-VEGF on Type 3 Macular Neovascularization: Long-Term Outcomes;Ophthalmic Research;2024-04-15

3. Volume-rendering three-dimensional image analysis of macular neovascularization in age-related macular degeneration;Eye;2023-12-01

4. Outcomes of Intentionally Suspending Treatment in Eyes With Advanced Neovascular Age-Related Macular Degeneration;American Journal of Ophthalmology;2023-12

5. Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre;Eye;2022-09-09